<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864782</url>
  </required_header>
  <id_info>
    <org_study_id>QL1604-301</org_study_id>
    <nct_id>NCT04864782</nct_id>
  </id_info>
  <brief_title>QL1604 Plus Chemotherapy Versus Chemotherapy in Subjects With Stage ⅣB, Recurrent, or Metastatic Cervical Cancer</brief_title>
  <official_title>A Study of QL1604 Plus Chemotherapy Versus Chemotherapy Plus Placebo With Stage ⅣB, Recurrent, or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of PD-1 Inhibitor (QL1604)&#xD;
      plus chemotherapy in patients with Stage Ⅳ, recurrent, or metastatic cervical cancer.&#xD;
      Possible chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus&#xD;
      carboplatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in 2 parts.The first stage is a single-arm clinical trial, and&#xD;
      the second stage is a controlled clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The first stage is a single-arm clinical trial, and the second stage is a controlled clinical trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>Up to 90 days from last dose</time_frame>
    <description>The incidence and severity of adverse events (AE),serious adverse events (SAE) and treatment-emergent adverse events (TEAEs) according to CTCAE V5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) as assessed by investigator based on RECIST v1.1 and iRECIST</measure>
    <time_frame>approximately 6 months</time_frame>
    <description>Objective response rate (ORR) as assessed by investigator based on RECIST v1.1 and iRECIST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) as assessed by investigator based on RECIST v1.1 and iRECIST and as assessed by independent radiology review based on RECIST v1.1</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Progression-free survival (PFS) is defined as time from the date of randomization to the date of first documentation of disease progression or death due to any cause(whichever occurs earlier)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Overall survival(OS) is defined as the time from randomization to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Objective response rate (ORR) as assessed by independent radiology review based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Duration of response(DOR) as assessed by investigator based on RECIST v1.1 and iRECIST,as assessed by independent radiology review based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progress (TTP)</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Time to progress (TTP) as assessed by investigator based on RECIST v1.1 and iRECIST,as assessed by independent radiology review based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of QL1604</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>Area under curve from zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of QL1604</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>Peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of QL1604</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>The trough value at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of QL1604</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of QL1604</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>Half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss of QL1604</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>Steady-state apparent volume of distribution based on plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT(total body clearance) of QL1604</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>Total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>approximately 1 years</time_frame>
    <description>The titer of anti-drug antibodies (ADA)and neutralizing antibodies(Nab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>before the first dose</time_frame>
    <description>Explore the correlation between curative effect and different biomarkers, such as PD-L1, TMB</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">458</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin Area Under the Curve (AUC) 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B-arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each 21-day cycle, participants receive an IV infusion of QL1604 200 mg plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B-arm2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo plus Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 plus cisplatin 70 mg/m^2 or paclitaxel 175 mg/m^2 plus carboplatin AUC 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QL1604</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B-arm1</arm_group_label>
    <other_name>PD-1 monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel injection</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B-arm1</arm_group_label>
    <arm_group_label>Cohort B-arm2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin/Carboplatin</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B-arm1</arm_group_label>
    <arm_group_label>Cohort B-arm2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years and ≤ 75 years&#xD;
&#xD;
          2. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          3. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          4. At least one measurable lesion (according to RECIST v1.1)&#xD;
&#xD;
          5. Cervical squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma&#xD;
             diagnosed by histopathology and confirmed by imaging as recurrent or stage ⅣB cervical&#xD;
             cancer.&#xD;
&#xD;
          6. No brain metastasis, or no meningeal metastasis.&#xD;
&#xD;
          7. Patients must have normal function as defined:&#xD;
&#xD;
               1. ANC≥1.5*10^9/L; PLT≥90*10^9/L, Hb≥90 g/L,&#xD;
&#xD;
               2. Total Bilirubin (TBIL)≤1.5*Upper Limit of Normal(ULN), Alanine Transaminase&#xD;
                  (ALT)and Aspartate Aminotransferase(AST)≤2.5*ULN.For liver metastasis patients,&#xD;
                  ALT and AST≤5*ULN,&#xD;
&#xD;
               3. Cr≤ 1.5*ULN, or creatinine clearance rate ≥50 mL/min,&#xD;
&#xD;
               4. Proteinuria &lt;2+，if proteinuria≥ 2+ and 24 hours total urine protein &lt; 1.0 g&#xD;
&#xD;
               5. LVEF≥ 50%.&#xD;
&#xD;
          8. Any unresolved AEs ≤ CTCAE Grade 1 (except alopecia).&#xD;
&#xD;
          9. Negative pregnancy test for females of child-bearing potentials.&#xD;
&#xD;
         10. Patients with reproductive function agreed to take effective contraceptive measures&#xD;
             during the treatment and in 6 months after the end of administration.&#xD;
&#xD;
         11. Patients must be able to understand and volunteer to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has received more than 2 courses of palliative chemotherapy for treatment of cervical&#xD;
             cancer.&#xD;
&#xD;
          2. Has received prior chemoradiotherapy within 3 months before enrollment,or has received&#xD;
             prior radiotherapy within 2 weaks before enrollment.&#xD;
&#xD;
          3. Has received prior surgery therapy within 2 weaks before enrollment,or has not&#xD;
             recovered from the effects of surgery therapy.&#xD;
&#xD;
          4. Is currently participating in or has participated in a study of an investigational&#xD;
             agent within 4 weeks before enrollment.&#xD;
&#xD;
          5. Has any active autoimmune diseases or a history of autoimmune diseases (such as the&#xD;
             following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis,&#xD;
             pituitary inflammation, vasculitis, nephritis, thyroid hyperfunction; patients with&#xD;
             vitiligo; complete remission of asthma in childhood, can be included without any&#xD;
             intervention after adulthood; asthma patients who require bronchodilators for medical&#xD;
             intervention cannot be included).&#xD;
&#xD;
          6. Is using immunosuppressive agents or systemic hormonal therapy to achieve&#xD;
             immunosuppressive purposes (agents amount &gt; 10 mg / day of prednisone or other&#xD;
             therapeutic hormones), and continue to use within 2 weeks before enrollment.&#xD;
&#xD;
          7. Known history of hypersensitivity to macromolecular protein preparation or any&#xD;
             components of the QL1604 formulation, or any components of the study drugs.&#xD;
&#xD;
          8. Has uncontrolled clinically significant cardiac and cerebral vascular diseases within&#xD;
             6 months before enrollment, including but not limited to the following: myocardial&#xD;
             infarction, severe or unstable angina, coronary artery/peripheral artery bypass&#xD;
             grafting, congestive heart failure, cerebrovascular accident (including transient&#xD;
             ischemic attack).&#xD;
&#xD;
          9. Symptomatic congestive heart failure (New York Heart Association Grade II-IV), or&#xD;
             NCI-CTCAE v5.0 ≥ 2 arrhythmia, atrial fibrillation of any grade, or clinically&#xD;
             significant supraventricular arrhythmia or ventricular arrhythmia requirement for&#xD;
             treatment or intervention.&#xD;
&#xD;
         10. Has active infection or an unexplained fever &gt; 38.5°C during screening visits(&#xD;
             subjects with tumor fever may be enrolled at the discretion of the investigator).&#xD;
&#xD;
         11. Hepatitis b surface antigen (HBsAg) positive and/or hepatitis b core antibody (HBcAb)&#xD;
             positive and HBVDNA&gt;103copies/ml, hepatitis c virus antibody positive .&#xD;
&#xD;
         12. Known history of human immunodeficiency virus (HIV) infection, or other acquired or&#xD;
             congenital immunodeficiency diseases,or has a history of organ transplantation (except&#xD;
             corneal transplantation).&#xD;
&#xD;
         13. Has been vaccinated with live anti-tumor vaccine, or have received anti-tumor&#xD;
             immunotherapy, or may receive other systemic anti-tumor treatments during the study&#xD;
             period.&#xD;
&#xD;
         14. Peripheral neuropathy≥ CTCAE Grade 2.&#xD;
&#xD;
         15. History of psychotropic substance abuse, alcoholism or drug abuse.&#xD;
&#xD;
         16. Has a clear history of neurological or mental disorders, including epilepsy or&#xD;
             dementia.&#xD;
&#xD;
         17. Patients with other malignancies witnin 5 years( except cured basal cell carcinoma of&#xD;
             skin cancer, papillary thyroid carcinoma).&#xD;
&#xD;
         18. At the discretion of the investigator, there are patients with serious concomitant&#xD;
             disease that compromises patient safety or affects the patient's completion of the&#xD;
             study,such as unable to be controlled within normal level following treatment of&#xD;
             anti-hypertension agents (systolic blood pressure &gt; 160 mmHg, diastolic blood pressure&#xD;
             &gt; 110 mmHg), serious diabetes, thyroid diseases, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meimei Si, MM</last_name>
    <phone>010-50813552</phone>
    <email>meimei.si@qilu-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jihong Liu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

